ENDURONYL FORTE
LOE ApproachingNDAORALTABLET
Approved
Aug 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENDURONYL FORTE is an oral tablet small-molecule NDA approved in 1961 by Abbott. The specific indication and mechanism of action are not publicly available in current databases, suggesting this is a legacy product with limited active promotion.
LOE Approaching
With LOE approaching and minimal current spending data, team size and hiring momentum for this brand are likely declining, indicating consolidation toward generic support or product line exit.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
1,850 linked jobs indicate Abbott maintains operational presence around ENDURONYL FORTE, primarily in manufacturing, engineering, and compliance. Career relevance is strongest in supply-chain and regulatory support roles rather than growth-oriented commercial or clinical functions.
Registered NurseClinical Specialist
Worked on ENDURONYL FORTE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.